睿知中国医院研究地图
候选清单

正在招募肺癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心广州医科大学附属第一医院First Affiliated Hospital of Guangzhou Medical University广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06461156,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Subjects with histologically or cytologically confirmed locally advanced or metastatic NSCLC

    入选标准第 2 条

  3. Cytotoxic chemotherapy, any other investigational drugs, traditional Chinese medicine with anti-tumor indications, or other anti-tumor drugs within 14 days prior to the first dose of HS-10504 or require continued treatment with these drugs during the study.

    排除标准第 5 条

    Any local radiotherapy 2 weeks prior to the first dose of study treatment; have received irradiation of more than 30% of bone marrow prior to the first dose

    排除标准第 6 条

  4. ECOG PS score: 0-1.

    入选标准第 6 条

  5. At least 1 target lesion according to RECIST 1.1.

    入选标准第 5 条

  6. Women who are breastfeeding or pregnant or planned to be pregnant during the study period.

    排除标准第 17 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06461156,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Males or females, aged ≥ 18 years.
  2. Subjects with histologically or cytologically confirmed locally advanced or metastatic NSCLC
  3. Progressive disease on or after prior treatment with EGFR-TKIs.
  4. Enrollment will be restricted to participants with evidence of EGFR-positive in tumor as determined by local or central testing.
  5. At least 1 target lesion according to RECIST 1.1.
  6. ECOG PS score: 0-1.
  7. Estimated life expectancy> 12 weeks.
  8. Men or women should be using adequate contraceptive measures throughout the study.
  9. Women must have the evidence of non-childbearing potential.
  10. Signed and dated Informed Consent Form.

排除标准:Exclusion Criteria:

  1. Subjects with known oncogenic driver genes other than EGFR.
  2. Subjects with mixed cell histologic or with phenotypic transformation.
  3. Treatment with any of the following:
  4. Prior or concurrent treatment with fourth-generation EGFR tyrosine kinase inhibitors.
  5. Cytotoxic chemotherapy, any other investigational drugs, traditional Chinese medicine with anti-tumor indications, or other anti-tumor drugs within 14 days prior to the first dose of HS-10504 or require continued treatment with these drugs during the study.
  6. Any local radiotherapy 2 weeks prior to the first dose of study treatment; have received irradiation of more than 30% of bone marrow prior to the first dose
  7. Uncontrolled pleural effusion or ascites or pericardial effusion.
  8. Major surgery within 4 weeks before the first dose.
  9. CNS metastases with symptomatic or active progression.
  10. Subjects who have any grade ≥2 residual toxicities from prior therapies.
  11. Subjects who have history of other primary malignancies.
  12. Inadequate bone marrow reserve or hepatic and renal functions.
  13. Subjects with severe or poorly controlled diabetes, cardiovascular diseases or hypertension; subjects with severe arteriovenous thrombotic events, severe infection, clinically significant bleeding symptoms or clinically significant gastrointestinal dysfunction.
  14. Hypersensitivity to any ingredient of HS-10504.
  15. Moderate to severe pulmonary diseases.
  16. Prior history of significant neurological or mental disorders.
  17. Women who are breastfeeding or pregnant or planned to be pregnant during the study period.
  18. Unlikely to comply with study procedures, restrictions, and requirements in the opinion of the investigator.
  19. Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments.

引自 ClinicalTrials.gov, NCT06461156, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06461156,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06461156